Investigator-Initiated Studies: The Sponsor Duties You Take On

At a glance

• Initiating your own trial does not make you a sponsor instead of an investigator. It makes you both, and 21 CFR 312.3 says so in the definition itself.
• Nothing is subtracted from the investigator column. The sponsor duties are added on top, and that added column is where IIT failures concentrate.
• Only an individual can be a sponsor-investigator. An institution cannot hold the role.
• Obligations written as “report to the sponsor” collapse when you are the sponsor. Reporting to yourself discharges nothing; the duties that matter are the ones running outward to FDA and the IRB.
• FDA inspects sponsor-investigators under the same bioresearch monitoring programme as clinical investigators, against both duty sets.

What a sponsor-investigator actually is

The regulation defines the role precisely, and the definition contains the whole argument of this page.

A sponsor-investigator means an individual who both initiates and conducts an investigation, and under whose immediate direction the investigational drug is administered or dispensed. The term does not include any person other than an individual. The requirements applicable to a sponsor-investigator under this part include both those applicable to an investigator and a sponsor (21 CFR §312.3).

Three things follow immediately.

The duties are additive, not substitutive. This is the sentence people miss. Becoming a sponsor does not relieve you of anything on the investigator side. You hold both sets simultaneously.

Only a person can hold the role. The term does not include any person other than an individual, so an institution, a department or a research group cannot be the sponsor-investigator. A named individual carries it.

“Initiates and conducts” is conjunctive. The role attaches to someone doing both. An investigator running someone else’s protocol under someone else’s IND is not a sponsor-investigator, and the distinction matters because the obligations that follow are substantial.

The column you already know, and the one you just acquired

Most investigators starting an IIT understand the investigator duties. They have signed Form FDA 1572 before, they know they are responsible for ensuring that an investigation is conducted according to the signed investigator statement, the investigational plan, and applicable regulations, and for protecting the rights, safety and welfare of subjects under their care (21 CFR §312.60). That column is familiar.

The sponsor column is the one that arrives unannounced. Part 312 states it in general terms: sponsors are responsible for selecting qualified investigators, providing them with the information they need to conduct an investigation properly, ensuring proper monitoring of the investigations, ensuring that the investigations are conducted in accordance with the general investigational plan and protocols contained in the IND, maintaining an effective IND with respect to the investigations, and ensuring that FDA and all participating investigators are promptly informed of significant new information (21 CFR §312.50).

Read that list as a job description you have just accepted in addition to your existing one. Selecting and informing investigators, when you may be the only investigator. Ensuring monitoring. Maintaining the IND. Keeping FDA informed.

ICH E6(R3) frames the sponsor obligation in similar terms and with the same emphasis on ensuring rather than performing: the sponsor should ensure that the trial design and trial conduct, the processes undertaken and the information and data generated are of sufficient quality to ensure reliable trial results, trial participants’ safety and appropriate decision making (ICH E6(R3) §3.9.1).

The sponsor duties most often dropped

Four in particular go missing in investigator-initiated work, and they are not obscure.

Monitoring. The sponsor shall monitor the progress of all clinical investigations being conducted under its IND (21 CFR §312.56). This is stated flatly, with no proportionality qualifier and no exemption for small academic studies. A sponsor-investigator running a single-site trial still owes monitoring of that trial. The uncomfortable structural point is that you cannot straightforwardly monitor yourself, which is why many institutions provide an independent monitor for IITs. If yours does not, the duty has not gone away; it is simply unmet.

Safety reporting outward. As an investigator you report adverse experiences to the sponsor. As the sponsor you must notify FDA and all participating investigators in an IND safety report of potential serious risks, from clinical trials or any other source, as soon as possible and in no case later than 15 calendar days after determining that the information qualifies for reporting (21 CFR §312.32). That 15-day clock is a sponsor obligation, it runs to FDA, and it exists whether or not anyone reminds you.

Maintaining the IND. Keeping an effective IND is on the sponsor list at §312.50. Protocol amendments, new investigators, annual reports and the general obligation to keep the submission current all sit with you now.

Record retention on both clocks. Investigator records are retained for two years following the date a marketing application is approved for the indication, or, if no application is filed or approved, until two years after the investigation is discontinued and FDA is notified (21 CFR §312.62). The sponsor obligation is stated separately: a sponsor shall retain the records and reports required by the part for two years after a marketing application is approved, or until two years after shipment and delivery of the drug for investigational use is discontinued and FDA has been so notified (21 CFR §312.57). You hold both, and the practical answer is the longer of them.

When the reporting loop collapses

This is the trap that distinguishes an IIT from an ordinary investigator role, and it is worth stating plainly because the regulations were not written with it in mind.

Many investigator obligations are phrased as duties owed to the sponsor. The Form FDA 1572 commitment is a clear example: the investigator commits to report to the sponsor adverse experiences that occur in the course of the investigation in accordance with 21 CFR §312.64 (21 CFR §312.53(c)(1)(vi)(e)). When you are the sponsor, that instruction becomes “report to yourself”, which is not a discharge of anything.

The resolution is not that the duty disappears. It is that the outward-facing obligations become the operative ones. The event you would have reported to a sponsor now has to be assessed by you, in your sponsor capacity, against the §312.32 criteria, and reported to FDA and to any participating investigators within 15 days if it qualifies. The internal handoff that would normally create a second pair of eyes is gone, and nothing replaces it automatically.

Two practical consequences follow. Build the second pair of eyes deliberately, whether through an institutional safety committee, an independent monitor, or a colleague with a defined review role. And write down which capacity you are acting in when you make a determination, because in an inspection the question will be what the sponsor concluded and when, not what the investigator noticed.

You can delegate the work, and you keep the duty

Most sponsor-investigators are not doing all of this alone. Institutions provide monitoring, safety support, regulatory affairs help, sometimes a full research office. That is sensible and it is permitted, but it changes who performs the work rather than who answers for it.

Under Part 312 the transfer route is formal. A sponsor may transfer responsibility for any or all of the obligations set forth in the part to a contract research organization, any such transfer shall be described in writing, and where not all obligations are transferred the writing is required to describe each obligation being assumed (21 CFR §312.52(a)). The sting is in the next clause: any obligation not covered by the written description shall be deemed not to have been transferred (21 CFR §312.52(a)).

ICH E6(R3) reaches the same place from the other direction. Any of the sponsor’s trial-related activities that are transferred to and assumed by a service provider should be documented in an agreement, and the sponsor’s trial-related activities that are not specifically transferred to and assumed by a service provider are retained by the sponsor (ICH E6(R3) §3.6.4). More broadly, where activities have been transferred or delegated to service providers, the responsibility for the conduct of the trial, including quality and integrity of the trial data, resides with the sponsor or investigator respectively (ICH E6(R3) Principle 10.2).

For an IIT this matters more than it does for a commercial trial, because the arrangements are usually informal. An institutional research office that helps with the IND is not thereby holding the IND obligation. A departmental colleague who reviews safety events has not assumed the §312.32 determination. Unless it is written down and specific, it is still yours, and the informality that makes academic support easy to obtain is exactly what leaves these obligations unallocated.

Multi-site IITs raise the stakes

The duties above are demanding for a single-site study. When an IIT runs across sites, two sponsor obligations that were nearly invisible become concrete.

The first is informing the people conducting the trial. Sponsors are responsible for providing investigators with the information they need to conduct an investigation properly, and for ensuring that FDA and all participating investigators are promptly informed of significant new information (21 CFR §312.50). With one site that duty collapses into your own knowledge. With several, it becomes a real distribution obligation with a real failure mode.

The second is safety distribution. The §312.32 obligation runs to FDA and to all participating investigators, defined as all investigators to whom the sponsor is providing drug under its INDs (21 CFR §312.32). A qualifying safety determination therefore has to reach every site within the same 15-day window, which requires a distribution mechanism decided in advance rather than improvised on day twelve.

How this is inspected

Sponsor-investigators are not inspected under a separate, gentler programme. FDA’s bioresearch monitoring compliance programme for clinical investigators applies to all six of FDA’s centres and addresses inspections of clinical investigators and sponsor-investigators who conduct FDA-regulated clinical studies (FDA BIMO 7348.811). The programme then treats the two collectively: clinical investigator and sponsor-investigator are referred to collectively and individually as clinical investigators throughout (FDA BIMO 7348.811).

Read together with §312.3, the position is clear. You are inspected as an investigator, and the sponsor requirements apply to you as well. An IIT that was run with excellent site conduct and no sponsor-side monitoring, safety reporting or IND maintenance is not a well-run trial with a paperwork gap. It is a trial missing half its regulatory obligations.

The qualification expectation applies in the ordinary way too: investigators should be qualified by education, training and experience to assume responsibility for the proper conduct of the trial and should provide evidence of such qualifications (ICH E6(R3) §2.1.1). Nothing in taking the sponsor role relaxes that.

Before first participant in

A short set of questions worth being able to answer, in writing, before enrolment opens. Each maps to an obligation above rather than to good practice in general.

• Who monitors this trial, and what record will that monitoring produce?
• Who assesses events against the §312.32 criteria, and how is the 15-day clock tracked from the date of determination?
• Who maintains the IND, and what is the process when the protocol is amended or an investigator is added?
• Where will records be held, for how long, and under whose name after you move institutions?
• Which decisions will you make in your sponsor capacity, and where will that be recorded?

If several of those have no answer, the trial is not ready, and the gap is on the sponsor side every time.

The most useful way to hold the role is to stop thinking of it as one job with extra paperwork. It is two jobs held by one person, and the regulation is explicit that neither is reduced by the presence of the other.

Sources

• 21 CFR Part 312, Investigational New Drug Application (current as of 4/14/2026)
• ICH E6(R3) Good Clinical Practice, version R3
• FDA Compliance Program 7348.811, Bioresearch Monitoring: Clinical Investigators and Sponsor-Investigators (implementation date 07/22/2020)